BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2026)

BridgeBio Pharma has disclosed Return on Capital Employed across 8 years of filings, most recently posting 155.72% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 155.72%, down 6250.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 155.72% (down 6250.0% YoY), and the FY2025 annual result was 81.82%, up 2069.0% from the prior year.
• Return on Capital Employed came in at 155.72% for Q1 2026 at BridgeBio Pharma, down from 77.07% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 72.0% in Q1 2022 to a low of 155.72% in Q1 2026.
• The 5-year median for Return on Capital Employed is 88.05% (2023), against an average of 94.74%.
• Across the five-year window, Return on Capital Employed soared 4251 bps in 2024 and plunged 6250 bps in 2026, its largest moves.
• BridgeBio Pharma's Return on Capital Employed stood at 92.38% in 2022, then sank by 44 bps to 132.95% in 2023, then jumped by 30 bps to 92.98% in 2024, then advanced by 17 bps to 77.07% in 2025, then tumbled by 102 bps to 155.72% in 2026.
• The last three Return on Capital Employed figures came in at 155.72% (Q1 2026), 77.07% (Q4 2025), and 74.14% (Q3 2025), per Business Quant data.